In-Vitro and In-Vivo Effects of the Local Anaesthetic Dibucaine on Malignant Hyperthermia - Susceptible and Normal Swine
- *Corresponding Author:
- Mark Ulrich Gerbershagen
Department of Anaesthesiology and Intensive Care Medicine
University Hospital Cologne Merheim
University of Witten-Herdecke, Germany
Tel: +49 221 890713916
Fax: +49 221 89073868
E-mail: [email protected]
Received date: October 17, 2011; Accepted date: December 02, 2011; Published date: December 07, 2011
Citation: Gerbershagen MU, Weißhorn R, Kolodzie K, Wappler F, Fiege M (2011) AIn-Vitro and In-Vivo Effects of the Local Anaesthetic Dibucaine on Malignant Hyperthermia–Susceptible and Normal Swine. J Anesthe Clinic Res 2:172. doi: 10.4172/2155-6148.1000172
Copyright: © 2011 Gerbershagen MU, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Ten case reports have described clinical signs and symptoms of malignant hyperthermia (MH) that developed following local anaesthetics. In this study, the In-Vitro effects of dibucaine, an amide local anaesthetic, were compared in skeletal-muscle samples from MH-susceptible (MHS) and normal (MHN) swine. In addition, we investigated the In-Vivo MH trigger potency of dibucaine in MHS swine. Methods: Trigger-free general anaesthesia was induced in six MHS and six MHN swine. Muscle biopsies were obtained. In the In-Vivo experiment, cumulative doses of dibucaine (1, 2, 4, 8, 16, and 32 mg/kg) were administered i.v. In the In-Vitro contracture test (IVCT), dibucaine was added cumulatively to muscle specimens from eight MHS and eight MHN muscles (bath concentrations: 0.1, 0.2, 0.4, 0.6, and 1.0 mmol/l). Results: In the In-Vivo test, no signs or symptoms of MH were observed. In-Vitro contractures developed in all muscle specimens, but they developed significantly faster and were more intense in MHS than in MHN muscles. Conclusion: Dibucaine is not a MH trigger in swine. The IVCT with dibucaine demonstrated overlaps between the diagnostic groups, so that the possibility of 100 % accurate discrimination between MHS and MHN individuals by this means does not seem likely.